Targeting neuroinflammation and ApoE issues in Alzheimer's disease using microRNA therapy
MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease
This study is exploring a new treatment for Alzheimer's disease that uses a tiny molecule called microRNA-223 to help reduce inflammation in the brain, and it could potentially improve thinking and memory for patients if it works well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project ID | NIH-11001224 on NIH RePORTER |
What this research studies
This research investigates the use of microRNA-223, a small regulatory RNA, to address neuroinflammation and ApoE dysregulation in Alzheimer's disease. The approach involves a novel delivery system using lipid nanoparticles to effectively target and modulate the activity of microRNA-223 in brain cells. By focusing on the relationship between microRNA-223 and the inflammatory response in the brain, the research aims to develop a therapeutic strategy that could mitigate the effects of Alzheimer's disease. Patients may benefit from this innovative treatment if it proves effective in reducing neuroinflammation and improving cognitive function.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk for developing Alzheimer's-related dementia.
Not a fit: Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that reduces inflammation and improves brain health in Alzheimer's patients.
How similar studies have performed: While microRNA therapies are a novel approach in Alzheimer's treatment, preliminary studies have shown promise in targeting neuroinflammation, suggesting potential for success.
Where this research is happening
Lexington, United States
- University of Kentucky — Lexington, United States (Active)
Researchers
- Principal investigator: Wang, Wang-Xia — University of Kentucky
- Study coordinator: Wang, Wang-Xia
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.